CRISPR Therapeutics (NASDAQ:CRSP) Upgraded to Sell at StockNews.com

StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP) to a sell rating in a research report sent to investors on Thursday morning.

A number of other analysts have also recently commented on CRSP. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Truist Financial dropped their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Stifel Nicolaus dropped their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Barclays dropped their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They issued a “buy” rating and a $90.00 price target on the stock. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $74.94.

CRISPR Therapeutics Stock Down 0.3 %

CRISPR Therapeutics stock traded down $0.14 during midday trading on Thursday, reaching $51.74. The stock had a trading volume of 939,509 shares, compared to its average volume of 1,454,078. The firm has a market capitalization of $4.40 billion, a PE ratio of -16.06 and a beta of 1.67. CRISPR Therapeutics has a 12 month low of $43.42 and a 12 month high of $91.10. The firm’s 50-day moving average price is $47.38 and its 200 day moving average price is $52.24.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the previous year, the firm earned ($1.41) earnings per share. Equities research analysts expect that CRISPR Therapeutics will post -5.57 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC grew its position in shares of CRISPR Therapeutics by 51.8% in the first quarter. Private Advisor Group LLC now owns 13,551 shares of the company’s stock valued at $923,000 after purchasing an additional 4,625 shares in the last quarter. Geneos Wealth Management Inc. grew its position in shares of CRISPR Therapeutics by 55.5% in the first quarter. Geneos Wealth Management Inc. now owns 871 shares of the company’s stock valued at $59,000 after purchasing an additional 311 shares in the last quarter. Oppenheimer & Co. Inc. grew its position in shares of CRISPR Therapeutics by 12.3% in the first quarter. Oppenheimer & Co. Inc. now owns 29,692 shares of the company’s stock valued at $2,024,000 after purchasing an additional 3,257 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of CRISPR Therapeutics in the first quarter valued at approximately $1,602,000. Finally, Reynders McVeigh Capital Management LLC grew its position in shares of CRISPR Therapeutics by 5.4% in the first quarter. Reynders McVeigh Capital Management LLC now owns 96,979 shares of the company’s stock valued at $6,611,000 after purchasing an additional 4,931 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.